|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AH02
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:brand
|
gptkb:Tamiflu
|
|
gptkbp:CASNumber
|
196618-13-0
|
|
gptkbp:category
|
antiviral drug
prodrug
neuraminidase inhibitor
|
|
gptkbp:chemicalFormula
|
C16H28N2O4
|
|
gptkbp:contraindication
|
hypersensitivity to oseltamivir
|
|
gptkbp:developer
|
gptkb:Gilead_Sciences
|
|
gptkbp:discoveredIn
|
1996
|
|
gptkbp:eliminationHalfLife
|
6-10 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
gptkb:Gilead_Sciences
|
|
gptkbp:form
|
capsule
oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oseltamivir
|
|
gptkbp:indication
|
prophylaxis of influenza
|
|
gptkbp:IUPACName
|
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
|
|
gptkbp:KEGGID
|
D08367
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
neuraminidase inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:notEffectiveAgainst
|
gptkb:COVID-19
common cold
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prodrugOf
|
oseltamivir carboxylate
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL123
65028
DB00198
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
headache
neuropsychiatric effects
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
R7T0KZ6CMO
|
|
gptkbp:usedFor
|
treatment of influenza A
treatment of influenza B
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Influenza_Virus
gptkb:Antiviral
|
|
gptkbp:bfsLayer
|
6
|